Key Highlights

  • Revenue was USD 72 thousand, with cost of revenues of USD 1.10 million.
  • Net loss was USD 5.84 million, compared with USD 3.58 million.
  • Loss per share was USD 0.09, compared with USD 0.07.
  • Total Assets were USD 68.21 million at September 30, 2026.

Microbot Medical (NASDAQ:MBOT) reported Revenue of USD 72 thousand for the third quarter of 2026, with cost of revenues of USD 1.10 million and a gross loss of USD 1.02 million. The net loss was USD 5.84 million, compared with USD 3.58 million in the prior-year quarter, and basic and diluted loss per share was USD 0.09, compared with USD 0.07.

The filing states that revenue decreased to USD 72 thousand from USD 241 thousand for the three months ended June 30, 2026, primarily due to a decrease in the number of units sold.

Operating Expenses

Research and development expenses, net, were USD 1.63 million, compared with USD 1.17 million. Sales and Marketing expenses were USD 2.00 million, compared with USD 531 thousand, and general and administrative expenses were USD 1.84 million, compared with USD 2.16 million.

The operating loss was USD 6.49 million, compared with USD 3.86 million. Financing income, net, was USD 652 thousand, compared with USD 284 thousand.

Nine-Month Results

For the nine months ended September 30, 2026, revenue was USD 418 thousand and cost of revenues was USD 2.08 million. Research and Development expenses, net, were USD 4.78 million, compared with USD 4.74 million, and sales and marketing expenses were USD 5.26 million, compared with USD 531 thousand.

General and administrative expenses were USD 5.30 million, compared with USD 5.33 million, and the operating loss was USD 17.00 million, compared with USD 10.61 million. The net loss was USD 15.14 million, compared with USD 9.68 million, and loss per share was USD 0.23, compared with USD 0.25.

Balance Sheet and Liquidity

Cash and cash equivalents were USD 2.29 million at September 30, 2026, compared with USD 3.91 million at December 31, 2025, and marketable securities were USD 59.54 million, compared with USD 74.68 million. Total assets were USD 68.21 million, compared with USD 81.54 million, and total liabilities were USD 4.76 million, compared with USD 3.99 million.

The filing states that the company had a cash, cash equivalents and marketable securities balance of approximately USD 61.83 million, excluding restricted cash, and that management concluded the available funds as of the Balance Sheet date are sufficient to fund operations. The filing describes an at-the-market offering agreement with H.C. Wainwright and a grant from the Israel Innovation Authority to finance development of the LIBERTY Manufacturing process.

The filing states that in relation to a Ministry of Economy grant of approximately USD 50 thousand, the company is obligated to pay royalties of 3% of future sales of LIBERTY up to the grant amount plus interest. The filing also describes an additional Israel Innovation Authority grant of approximately NIS 2.15 million, approximately USD 673 thousand, which was approved on July 15, 2025, with approximately USD 587 thousand received during 2025 and 2026. Total current assets were USD 66.87 million, compared with USD 79.82 million.

Microbot Medical Q3 2026 Earnings: Key Takeaways

Microbot Medical reported third quarter 2026 revenue of USD 72 thousand, a net loss of USD 5.84 million and a loss per share of USD 0.09. Total assets were USD 68.21 million at September 30, 2026.